Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

Obesity Clinical Trial

Official title:

Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02745925
• Other study ID #: Fe_Abs_Ibu
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: December 2018

Study information

• Verified date: October 2019
• Source: Swiss Federal Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main iron regulatory protein in the human metabolism is hepcidin. In normal weight, healthy subjects, hepcidin is regulated through the iron status of the body: low iron status results in low hepcidin concentrations, which facilitates dietary iron absorption. In obesity, which is an inflammatory state, hepcidin concentrations are increased and iron absorption is reduced despite low iron stores, leading to iron deficiency over time. Whether lowering the chronic low-grade inflammation during a limited treatment period and thereby lowering hepcidin concentration can improve iron absorption is uncertain.

Description:

In states of high hepcidin concentration, intestinal iron absorption (through enterocytes) and recycling of iron (through macrophages) is reduced. The extent to which non-heme iron is absorbed from the diet is influenced by the composition of the diet. Ascorbic acid is a potent enhancer of non-heme iron absorption. It's mechanism of action is luminal reduction of dietary ferric iron (Fe3+) to more soluble ferrous iron (Fe2+). A study in the inestigator's laboratory showed that the enhancing effect of ascorbic acid on non-heme iron absorption is reduced in overweight and obese individuals. Possible explanations for this fact are the different sites of action of ascorbic acid and serum hepcidin on the enterocytes in dietary iron absorption. Increased hepcidin reduces iron efflux into the circulation at the basolateral membrane of the enterocyte. Therefore the improved iron transport into enterocytes through ascorbic acid at the luminal side (via the divalent metal transporter (DMT)-1), by reducing Fe3+ to Fe2+ seems to be less successful. To improve iron absorption in obese subjects, an intervention at the basolateral membrane of the enterocyte would be needed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)

• pre-menopausal

• no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity

• no-smoking

Exclusion Criteria:

• Diagnosed chronic disease or gastrointestinal disorders

• Metabolic disorders (e.g. diabetes)

• Regular use of medication (except oral contraceptives)

• Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study

• Pregnancy or lactation

Related Conditions & MeSH terms

• Inflammation
• Obesity

Intervention

Drug:
• Ibuprofen

Locations

Country	Name	City	State
Switzerland	Human Nutrition Laboratory ETH Zurich	Zurich

Sponsors (2)

Lead Sponsor	Collaborator
Swiss Federal Institute of Technology	University of Monterrey, Mexico

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fractional iron absorption	The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.	Days 15 and 45
Secondary	Plasma ferritin		Days 1, 15, 30, 45
Secondary	Hemoglobin		Days 1, 15, 30, 45
Secondary	Transferrin receptor		Days 1, 15, 30, 45
Secondary	Hepcidin		Days 1, 15, 30, 45
Secondary	c-reactive protein		Days 1, 15, 30, 45
Secondary	interleukin-6		Days 1, 15, 30, 45
Secondary	alpha-1-acid-glycoprotein		Days 1, 15, 30, 45